All News
Will AI put me out of a job?
The development of AI and other technologies brings new possibilities for optimizing diagnosis, management and has potential for improving outcomes in RA. At RheumNow Live 2025, Dr. Jeff Curtis, University of Alabama at Birmingham, presented a talk on, "AI applied to Rheumatoid Arthritis Care: Practically (Not) Perfect".
Read Article
Obinutuzumab Efficacy in Active Lupus Nephritis
A phase 3, randomized controlled trial of an anti-CD20 monoclonal antibody, obinutuzumab, was shown to be effective and safe in patients with active lupus nephritis.
Read Article
Cannabis Hospitalizations and Mortality Risk
A Canadian population, retrospective cohort study shows individuals needing hospital-based (emergency department or hospitalization) care for a cannabis use disorder (CUD) were at increased risk of death.
Read Article
-HS ttx👇
1. Lifestyle changes: smoking cessation, obesity.
2. Management of comorbidities.
3. 🔍HS- related autoimmune disorders.
4. FDA approved biologics:
-Adalimumab (PIONEER 1&2)
-Secukinumab (SUNRISE, SUNSHINE)
-Bimekizumab (BE HEARD 1&2)
"Theres no such… https://t.co/G5Voxrm3Kt https://t.co/dLGtoFZMd1
Links:
Adela Castro AdelaCastro222 ( View Tweet)
Combination therapy in PsA . Regulatory and reimbursement issues may inhibit such strategies (and potential adverse event concerns) but anecdotal evidence would suggest a role in difficult to treat cases. @RheumNow #RNL2025 https://t.co/IIoUiJyP95
Richard Conway RichardPAConway ( View Tweet)
#RNL2025 @RheumNow
JAKi in DM:
@JuliePaikMD- 10 DM pts open label on JAKi. 7/10 improved from mod/severe to mild. In 96wk extension, 6 of 7 continued response
145 case reports for tofa, bari, ruxolitinib.
Role in helping calcinosis? Pruritu?
Brepocitinib (JAK1/TYK2i) study
Eric Dein ericdeinmd ( View Tweet)
#HOT #topic
Will #Rx of #PsO PREVENT onset of #PsA
Well, maybe 🤔
Alexis R Ogdie @RheumNow #RNL2025
70% of #psoriatic #arthritis is preceded by #psoriasis
Still a bit of a debate re prevention of PsA https://t.co/7bce8kcjdr
Janet Pope Janetbirdope ( View Tweet)
FDA has approved Journavx (suzetrigine) 50 mg tablets, 1st in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, before pain signals… https://t.co/qjtr4yz8Ot https://t.co/RUZmLgsmTv
Dr. John Cush RheumNow ( View Tweet)
Break a leg! Or a #hip
#AVN risk occurs even at 1 month of high / moderate dose #glucocorticoids
Shown by Michelle Petri @RheumNow #RNL2025
Risk in SLE is likely
👇
#disease #activity
And
#steroids
#SLE #systemic #lupus #erythematosus #steroids https://t.co/4EsQw9tY1u
Janet Pope Janetbirdope ( View Tweet)
Even a #SLE expert who wants all #lupus Pts on
No #chronic #prednisone
Realizes you can’t get everyone off #glucocorticoids
18% May be on chronic #steroids
But she keeps trying to taper
Michelle Petri
#RNL2025 @RheumNow https://t.co/SNP6Eep731
Janet Pope Janetbirdope ( View Tweet)
M. Petri on Steroids in SLE👇
-Organ damage is higher in AA vs Caucasians-driven by CS
-CV risk increase is dose dependent:
>10 mg =2x risk
>20mg =5x risk
-Increase prednisone by 10mg =30% increased risk for organ damage! 🤯
-20mg/day >1m increases risk for… https://t.co/fZVjS7JQBL
Adela Castro AdelaCastro222 ( View Tweet)
Wise person once said
If you don’t take your medications,
THEY DON’T WORK!
Shocking 1 in 3 nonadherence with
#hydroxychloroquine
By drug levels
In young Pts with
#SLE #lupus
Michelle Petri @RheumNow #RNL2025 https://t.co/H5izbnW0qU
Janet Pope Janetbirdope ( View Tweet)
Michele Petri @RheumNow #RNL2025
1 mg of prednisone -> 3% increased risk of damage
Taper quickly, withdrawal slowly
Make sure background therapy is on - monitor therapy with HCQ levels, early use of additional Rx https://t.co/pjFNcg99ed
Eric Dein ericdeinmd ( View Tweet)
Who’s liable for an incorrect #AI diagnosis or medical advice? @rheumnow #RNL2025 @RADoctor
TheDaoIndex KDAO2011 ( View Tweet)
AI models require good Positive Predictive Value (PPV)
But: PPV decreases as prevalence decreases
- In choosing a successful biologic:
Harder to predict more challenging patients (multiple failures, co-morbidities, etc) - ACR50 non-response is higher
J Curtis
@RheumNow #RNL2025 https://t.co/SdJ0FHVuSC
Eric Dein ericdeinmd ( View Tweet)
Late onset RA (LORA) aka RA diagnosed at an older age — pts have higher inflammatory markers, presents like PMR; they also have polypharmacy, comorbidities, frailty, etc that can complicate management
@UnaMakris #RNL2025 @RheumNow #GeriRheum https://t.co/zqEcyg2ejw
TheDaoIndex KDAO2011 ( View Tweet)
Can #AI help us determine the
👇
Right drug
At
Right time
Pipe dream?
Or to use #artificial #intelligence term
➡️ a #hallucination?
garbage in ➡️➡️garbage out
Most predictions of drug response are same: multimorbid multiRx failures
Nonadherent poverty #RNL25 @RheumNow https://t.co/70SRp8BnCl
Janet Pope Janetbirdope ( View Tweet)
Facing challenges in diagnosing idiopathic inflammatory myopathies? Check out our recent webinar to hear from Stanley J. Naides, MD, FACP, FACR, as he explores the role of autoantibody testing in autoimmune myositis diagnosis and phenotyping. Sponsored by LabCorp Rx. #Myositis… https://t.co/4jMevolO3k https://t.co/ObWPR8QFW2
Dr. John Cush RheumNow ( View Tweet)
Rituximab is FDA approved for treatment of moderate to severe pemphigus, but 20% may relapse in 1st Yr. Study of 87 pts shows the efficacy of repeat 6 mos RTX in A) those with persistent Dz activity and B) anyone w/ predictors of relapse (PDAI score, DSG1 or DSG3 abs)… https://t.co/IhqdGWVcdp https://t.co/MKhDpa5zHv
Dr. John Cush RheumNow ( View Tweet)
Dannish study of 1 million infants, exposed vs unexposed to systemic glucocorticoids shows prenatal GC exposure assoc w/ higher risk of autism (RR 1.5), intellectual disability (1.3), ADHD (1.3), mood/anxiety (1.3). Same risk for 290K mothers w/ autoimmune/inflamm Dz… https://t.co/bXL3YqCIYZ https://t.co/psNVENXRPs
Dr. John Cush RheumNow ( View Tweet)
